Skip to content

Enhancing placebo effects in pain and itch through oxytocin

Enhancing placebo effects in pain and itch through oxytocin - Placebo effects and oxytocin

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON42756
Enrollment
80
Registered
2016-03-23
Start date
2016-04-08
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Het onderzoek wordt bij gezonde personen uitgevoerd. Het onderzoek kan voor nieuwe inzichten zorgen bij therapeutische interventies voor pijn en jeuk. not applicable

Interventions

In the oxytocin with suggestions and oxytocin without suggestions groups, participants will receive a 24 IU dose of oxytocin via a nasal spray. In the placebo groups, participants will receive a pla

Sponsors

Universiteit Leiden
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Female between 18 and 35 years old - Good understanding of written and spoken Dutch

Exclusion criteria

Exclusion criteria: - Refusal to give written informed consent - Pregnancy or breast feeding - Conditions that might interfere with the participant's safety and/or the study protocol: severe somatic or psychological morbidity (e.g., heart and lung diseases, or DSM-IV psychiatric disorders, Raynaud*s phenomenon) - Chronic or acute itch or pain complaints - Current use of analgesics, anti-inflammatory drugs, antihistamines, antibiotics

Design outcomes

Primary

MeasureTime frame
The main study parameters are self-reported pain in response to the Cold Pressor Test and self-reported itch in response to the histamine iontophoresis.

Secondary

MeasureTime frame
Secondary parameters are skin temperature, flare response, and wheal size in response to the histamine iontophoresis, unpleasantness ratings in response to the Cold Pressor Task. Furthermore, the possible influence of psychological parameters on outcomes will be explored as well.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)